Breast Neoplasms Clinical Trials in Nashville, Tennessee

9 studies are recruiting for breast neoplasms in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

   This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Tennessee Oncology, Nashville, Tennessee

   Locations

   202 in total

   Run by

   BioNTech SE

   See if you can join NCT07173751 on ClinicalTrials.gov

2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

   Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   SCRI Oncology Partners ( Site 7005), Nashville, Tennessee

   Locations

   325 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06966700 on ClinicalTrials.gov

3. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

   Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people toler…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   SCRI Oncology Partners ( Site 7000), Nashville, Tennessee

   Locations

   17 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06797635 on ClinicalTrials.gov

4. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

   This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was design…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   86 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT05386108 on ClinicalTrials.gov

5. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

   The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute SCRI, Nashville, Tennessee

   Locations

   360 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07174336 on ClinicalTrials.gov

6. A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

   This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. S…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Tennessee Oncology, Nashville, Tennessee

   Locations

   89 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07287098 on ClinicalTrials.gov

7. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt, Nashville, Tennessee

   Locations

   49 in total

   Run by

   Natera, Inc.

   See if you can join NCT07214532 on ClinicalTrials.gov

8. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

   Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   SCRI Oncology Partners ( Site 7000), Nashville, Tennessee

   Locations

   199 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07060807 on ClinicalTrials.gov

9. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov